ホーム>>Signaling Pathways>> Neuroscience>> Serotonin Transporter>>Levomilnacipran (hydrochloride)

Levomilnacipran (hydrochloride) (Synonyms: (1S-cis)-Milnacipran)

カタログ番号GC44057

ミルナシプラン (1S-cis) 塩酸塩は、線維筋痛症の臨床治療に使用されるセロトニン-ノルエピネフリン再取り込み阻害剤 (SNRI) です。

Products are for research use only. Not for human use. We do not sell to patients.

Levomilnacipran (hydrochloride) 化学構造

Cas No.: 175131-60-9

サイズ 価格 在庫数 個数
10mM (in 1mL Water)
$77.00
在庫あり
5mg
$70.00
在庫あり
10mg
$105.00
在庫あり
50mg
$315.00
在庫あり

Tel:(909) 407-4943 Email: sales@glpbio.com

顧客レビュー

カスタマーレビューに基づきます。

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Description Chemical Properties Product Documents Related Products

Levomilnacipran is an active enantiomer of the serotonin (5-HT) and norepinephrine (NE) reuptake inhibitor milnacipran . It binds to the 5-HT and NE transporters (Kis = 11.2 and 92.2 nM, respectively, for human recombinant transporters) and inhibits reuptake in vitro (IC50s = 19 and 10.5 nM, respectively). It is selective for 5-HT and NE transporters over DAT (Ki = >10,000 nM for human recombinant DAT) and 23 receptors (Kis = ≥10,000 nM). Levomilnacipran increases extracellular levels of 5-HT and NE in rat cortex with minimal effective doses (MEDs) of 20 and 10 mg/kg, respectively. It decreases immobility in the forced swim and tail suspension tests (MEDs = 20 and 2.5 mg/kg, respectively) without increasing locomotor activity. Formulations containing levomilnacipran have been used in the treatment of major depressive disorder.

レビュー

Review for Levomilnacipran (hydrochloride)

Average Rating: 5 ★★★★★ (Based on Reviews and 21 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for Levomilnacipran (hydrochloride)

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.